HCA Healthcare, Inc.
HCA Healthcare, Inc. HCA Peers
See (HCA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCA | $380.53 | +1.69% | 90.9B | 16.57 | $22.80 | +0.73% |
| BKDT | $77.60 | +0.00% | 16.6B | N/A | N/A | N/A |
| FMS | $28.01 | +0.99% | 16.5B | 23.22 | $1.21 | +2.80% |
| THC | $174.38 | +3.18% | 16B | 11.06 | $15.60 | N/A |
| SOLV | $74.98 | +0.03% | 12.9B | 34.38 | $2.17 | N/A |
| EHC | $121.47 | +0.66% | 12.2B | 25.01 | $4.86 | +0.55% |
| UHS | $180.56 | +2.77% | 11.4B | 9.96 | $17.81 | +0.45% |
| DVA | $142.33 | +1.40% | 10.7B | 14.00 | $10.08 | N/A |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| ENSG | $154.07 | +1.02% | 8.8B | 29.02 | $5.30 | +0.16% |
Stock Comparison
HCA vs BKDT Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, BKDT has a market cap of 16.6B. Regarding current trading prices, HCA is priced at $380.53, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas BKDT's P/E ratio is N/A. In terms of profitability, HCA's ROE is -2.36%, compared to BKDT's ROE of -0.96%. Regarding short-term risk, HCA is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs FMS Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, FMS has a market cap of 16.5B. Regarding current trading prices, HCA is priced at $380.53, while FMS trades at $28.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas FMS's P/E ratio is 23.22. In terms of profitability, HCA's ROE is -2.36%, compared to FMS's ROE of +0.04%. Regarding short-term risk, HCA is less volatile compared to FMS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs THC Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, THC has a market cap of 16B. Regarding current trading prices, HCA is priced at $380.53, while THC trades at $174.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas THC's P/E ratio is 11.06. In terms of profitability, HCA's ROE is -2.36%, compared to THC's ROE of +0.37%. Regarding short-term risk, HCA is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs SOLV Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, SOLV has a market cap of 12.9B. Regarding current trading prices, HCA is priced at $380.53, while SOLV trades at $74.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas SOLV's P/E ratio is 34.38. In terms of profitability, HCA's ROE is -2.36%, compared to SOLV's ROE of +0.12%. Regarding short-term risk, HCA is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs EHC Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, EHC has a market cap of 12.2B. Regarding current trading prices, HCA is priced at $380.53, while EHC trades at $121.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas EHC's P/E ratio is 25.01. In terms of profitability, HCA's ROE is -2.36%, compared to EHC's ROE of +0.25%. Regarding short-term risk, HCA is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs UHS Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, UHS has a market cap of 11.4B. Regarding current trading prices, HCA is priced at $380.53, while UHS trades at $180.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas UHS's P/E ratio is 9.96. In terms of profitability, HCA's ROE is -2.36%, compared to UHS's ROE of +0.18%. Regarding short-term risk, HCA is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs DVA Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, DVA has a market cap of 10.7B. Regarding current trading prices, HCA is priced at $380.53, while DVA trades at $142.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas DVA's P/E ratio is 14.00. In terms of profitability, HCA's ROE is -2.36%, compared to DVA's ROE of +3.94%. Regarding short-term risk, HCA is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs OSH Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, HCA is priced at $380.53, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas OSH's P/E ratio is -17.65. In terms of profitability, HCA's ROE is -2.36%, compared to OSH's ROE of +4.64%. Regarding short-term risk, HCA is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs ENSG Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, ENSG has a market cap of 8.8B. Regarding current trading prices, HCA is priced at $380.53, while ENSG trades at $154.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas ENSG's P/E ratio is 29.02. In terms of profitability, HCA's ROE is -2.36%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, HCA is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs CHE Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, CHE has a market cap of 8.1B. Regarding current trading prices, HCA is priced at $380.53, while CHE trades at $559.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas CHE's P/E ratio is 27.13. In terms of profitability, HCA's ROE is -2.36%, compared to CHE's ROE of +0.26%. Regarding short-term risk, HCA is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs LHCG Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, HCA is priced at $380.53, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas LHCG's P/E ratio is 82.83. In terms of profitability, HCA's ROE is -2.36%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, HCA is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs OPCH Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, OPCH has a market cap of 5.2B. Regarding current trading prices, HCA is priced at $380.53, while OPCH trades at $32.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas OPCH's P/E ratio is 25.60. In terms of profitability, HCA's ROE is -2.36%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, HCA is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs AMED Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, AMED has a market cap of 3.2B. Regarding current trading prices, HCA is priced at $380.53, while AMED trades at $98.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas AMED's P/E ratio is 36.17. In terms of profitability, HCA's ROE is -2.36%, compared to AMED's ROE of +0.10%. Regarding short-term risk, HCA is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs SGRY Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, SGRY has a market cap of 2.8B. Regarding current trading prices, HCA is priced at $380.53, while SGRY trades at $21.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas SGRY's P/E ratio is -14.18. In terms of profitability, HCA's ROE is -2.36%, compared to SGRY's ROE of -0.10%. Regarding short-term risk, HCA is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs ADUS Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, ADUS has a market cap of 2.1B. Regarding current trading prices, HCA is priced at $380.53, while ADUS trades at $115.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas ADUS's P/E ratio is 26.12. In terms of profitability, HCA's ROE is -2.36%, compared to ADUS's ROE of +0.08%. Regarding short-term risk, HCA is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs ACHC Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, ACHC has a market cap of 2B. Regarding current trading prices, HCA is priced at $380.53, while ACHC trades at $21.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas ACHC's P/E ratio is 10.81. In terms of profitability, HCA's ROE is -2.36%, compared to ACHC's ROE of +0.06%. Regarding short-term risk, HCA is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs LFST Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, LFST has a market cap of 2B. Regarding current trading prices, HCA is priced at $380.53, while LFST trades at $5.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas LFST's P/E ratio is -56.44. In terms of profitability, HCA's ROE is -2.36%, compared to LFST's ROE of -0.02%. Regarding short-term risk, HCA is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs SEM Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, SEM has a market cap of 1.9B. Regarding current trading prices, HCA is priced at $380.53, while SEM trades at $15.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas SEM's P/E ratio is 24.24. In terms of profitability, HCA's ROE is -2.36%, compared to SEM's ROE of +0.10%. Regarding short-term risk, HCA is less volatile compared to SEM. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs ARDT Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, ARDT has a market cap of 1.9B. Regarding current trading prices, HCA is priced at $380.53, while ARDT trades at $13.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas ARDT's P/E ratio is 7.92. In terms of profitability, HCA's ROE is -2.36%, compared to ARDT's ROE of +0.24%. Regarding short-term risk, HCA is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs AMEH Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, HCA is priced at $380.53, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas AMEH's P/E ratio is 39.25. In terms of profitability, HCA's ROE is -2.36%, compared to AMEH's ROE of +0.07%. Regarding short-term risk, HCA is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs NHC Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, NHC has a market cap of 1.7B. Regarding current trading prices, HCA is priced at $380.53, while NHC trades at $109.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas NHC's P/E ratio is 15.76. In terms of profitability, HCA's ROE is -2.36%, compared to NHC's ROE of +0.11%. Regarding short-term risk, HCA is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs BKD Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, BKD has a market cap of 1.6B. Regarding current trading prices, HCA is priced at $380.53, while BKD trades at $6.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas BKD's P/E ratio is -6.72. In terms of profitability, HCA's ROE is -2.36%, compared to BKD's ROE of -0.96%. Regarding short-term risk, HCA is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs ASTH Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, ASTH has a market cap of 1.2B. Regarding current trading prices, HCA is priced at $380.53, while ASTH trades at $24.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas ASTH's P/E ratio is 33.86. In terms of profitability, HCA's ROE is -2.36%, compared to ASTH's ROE of +0.07%. Regarding short-term risk, HCA is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs USPH Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, HCA is priced at $380.53, while USPH trades at $79.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas USPH's P/E ratio is 36.15. In terms of profitability, HCA's ROE is -2.36%, compared to USPH's ROE of +0.06%. Regarding short-term risk, HCA is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs MD Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, MD has a market cap of 1.2B. Regarding current trading prices, HCA is priced at $380.53, while MD trades at $13.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas MD's P/E ratio is -13.62. In terms of profitability, HCA's ROE is -2.36%, compared to MD's ROE of -0.11%. Regarding short-term risk, HCA is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs HCSG Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, HCSG has a market cap of 1.1B. Regarding current trading prices, HCA is priced at $380.53, while HCSG trades at $14.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas HCSG's P/E ratio is 27.07. In terms of profitability, HCA's ROE is -2.36%, compared to HCSG's ROE of +0.08%. Regarding short-term risk, HCA is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs PNTG Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, PNTG has a market cap of 1B. Regarding current trading prices, HCA is priced at $380.53, while PNTG trades at $29.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas PNTG's P/E ratio is 38.28. In terms of profitability, HCA's ROE is -2.36%, compared to PNTG's ROE of +0.11%. Regarding short-term risk, HCA is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs AGL Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, AGL has a market cap of 956.2M. Regarding current trading prices, HCA is priced at $380.53, while AGL trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas AGL's P/E ratio is -3.73. In terms of profitability, HCA's ROE is -2.36%, compared to AGL's ROE of -0.44%. Regarding short-term risk, HCA is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs AVAH Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, AVAH has a market cap of 939.4M. Regarding current trading prices, HCA is priced at $380.53, while AVAH trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas AVAH's P/E ratio is 160.50. In terms of profitability, HCA's ROE is -2.36%, compared to AVAH's ROE of -0.12%. Regarding short-term risk, HCA is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs AMN Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, AMN has a market cap of 805.1M. Regarding current trading prices, HCA is priced at $380.53, while AMN trades at $21.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas AMN's P/E ratio is -4.86. In terms of profitability, HCA's ROE is -2.36%, compared to AMN's ROE of -0.21%. Regarding short-term risk, HCA is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs INNV Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, INNV has a market cap of 534.7M. Regarding current trading prices, HCA is priced at $380.53, while INNV trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas INNV's P/E ratio is -16.50. In terms of profitability, HCA's ROE is -2.36%, compared to INNV's ROE of -0.12%. Regarding short-term risk, HCA is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs CYH Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, CYH has a market cap of 488.3M. Regarding current trading prices, HCA is priced at $380.53, while CYH trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas CYH's P/E ratio is -0.95. In terms of profitability, HCA's ROE is -2.36%, compared to CYH's ROE of +0.30%. Regarding short-term risk, HCA is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs EHAB Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, EHAB has a market cap of 482.6M. Regarding current trading prices, HCA is priced at $380.53, while EHAB trades at $9.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas EHAB's P/E ratio is -3.44. In terms of profitability, HCA's ROE is -2.36%, compared to EHAB's ROE of -0.31%. Regarding short-term risk, HCA is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs TALKW Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, TALKW has a market cap of 481.6M. Regarding current trading prices, HCA is priced at $380.53, while TALKW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas TALKW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -2.36%, compared to TALKW's ROE of -0.04%. Regarding short-term risk, HCA is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs AUNA Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, AUNA has a market cap of 471.5M. Regarding current trading prices, HCA is priced at $380.53, while AUNA trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas AUNA's P/E ratio is 10.11. In terms of profitability, HCA's ROE is -2.36%, compared to AUNA's ROE of +0.07%. Regarding short-term risk, HCA is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs SNDA Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, SNDA has a market cap of 460.3M. Regarding current trading prices, HCA is priced at $380.53, while SNDA trades at $24.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas SNDA's P/E ratio is -6.72. In terms of profitability, HCA's ROE is -2.36%, compared to SNDA's ROE of -0.53%. Regarding short-term risk, HCA is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs TALK Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, TALK has a market cap of 460.1M. Regarding current trading prices, HCA is priced at $380.53, while TALK trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas TALK's P/E ratio is 137.50. In terms of profitability, HCA's ROE is -2.36%, compared to TALK's ROE of -0.04%. Regarding short-term risk, HCA is less volatile compared to TALK. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs CCRN Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, CCRN has a market cap of 429.8M. Regarding current trading prices, HCA is priced at $380.53, while CCRN trades at $13.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas CCRN's P/E ratio is -24.28. In terms of profitability, HCA's ROE is -2.36%, compared to CCRN's ROE of -0.04%. Regarding short-term risk, HCA is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs AONC Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, AONC has a market cap of 392.6M. Regarding current trading prices, HCA is priced at $380.53, while AONC trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas AONC's P/E ratio is -15.12. In terms of profitability, HCA's ROE is -2.36%, compared to AONC's ROE of +0.25%. Regarding short-term risk, HCA is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs AIRS Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, AIRS has a market cap of 296.2M. Regarding current trading prices, HCA is priced at $380.53, while AIRS trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas AIRS's P/E ratio is -16.36. In terms of profitability, HCA's ROE is -2.36%, compared to AIRS's ROE of -0.21%. Regarding short-term risk, HCA is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs CMPS Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, CMPS has a market cap of 247M. Regarding current trading prices, HCA is priced at $380.53, while CMPS trades at $2.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas CMPS's P/E ratio is -1.34. In terms of profitability, HCA's ROE is -2.36%, compared to CMPS's ROE of -0.72%. Regarding short-term risk, HCA is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs TOIIW Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, TOIIW has a market cap of 233.4M. Regarding current trading prices, HCA is priced at $380.53, while TOIIW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas TOIIW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -2.36%, compared to TOIIW's ROE of -4.83%. Regarding short-term risk, HCA is more volatile compared to TOIIW. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs CSU Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, HCA is priced at $380.53, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas CSU's P/E ratio is 0.67. In terms of profitability, HCA's ROE is -2.36%, compared to CSU's ROE of +2.23%. Regarding short-term risk, HCA is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs TOI Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, TOI has a market cap of 205.9M. Regarding current trading prices, HCA is priced at $380.53, while TOI trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas TOI's P/E ratio is -3.20. In terms of profitability, HCA's ROE is -2.36%, compared to TOI's ROE of -4.83%. Regarding short-term risk, HCA is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs JYNT Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, JYNT has a market cap of 177.7M. Regarding current trading prices, HCA is priced at $380.53, while JYNT trades at $11.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas JYNT's P/E ratio is -116.10. In terms of profitability, HCA's ROE is -2.36%, compared to JYNT's ROE of -0.43%. Regarding short-term risk, HCA is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs DCGO Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, DCGO has a market cap of 167.5M. Regarding current trading prices, HCA is priced at $380.53, while DCGO trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas DCGO's P/E ratio is -169.00. In terms of profitability, HCA's ROE is -2.36%, compared to DCGO's ROE of -0.00%. Regarding short-term risk, HCA is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs BTMD Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, BTMD has a market cap of 163.9M. Regarding current trading prices, HCA is priced at $380.53, while BTMD trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas BTMD's P/E ratio is 7.38. In terms of profitability, HCA's ROE is -2.36%, compared to BTMD's ROE of -0.19%. Regarding short-term risk, HCA is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs FVE Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, HCA is priced at $380.53, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas FVE's P/E ratio is -5.64. In terms of profitability, HCA's ROE is -2.36%, compared to FVE's ROE of -0.15%. Regarding short-term risk, HCA is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs KDLYW Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, HCA is priced at $380.53, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas KDLYW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -2.36%, compared to KDLYW's ROE of -1.46%. Regarding short-term risk, HCA is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs MODV Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, MODV has a market cap of 50.5M. Regarding current trading prices, HCA is priced at $380.53, while MODV trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas MODV's P/E ratio is -0.22. In terms of profitability, HCA's ROE is -2.36%, compared to MODV's ROE of +6.87%. Regarding short-term risk, HCA is less volatile compared to MODV. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs ALR Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, HCA is priced at $380.53, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas ALR's P/E ratio is -1.11. In terms of profitability, HCA's ROE is -2.36%, compared to ALR's ROE of -0.15%. Regarding short-term risk, HCA is less volatile compared to ALR. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs CCEL Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, CCEL has a market cap of 42.1M. Regarding current trading prices, HCA is priced at $380.53, while CCEL trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas CCEL's P/E ratio is 520.50. In terms of profitability, HCA's ROE is -2.36%, compared to CCEL's ROE of -0.01%. Regarding short-term risk, HCA is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs IMAC Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, HCA is priced at $380.53, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas IMAC's P/E ratio is -2.27. In terms of profitability, HCA's ROE is -2.36%, compared to IMAC's ROE of +2.46%. Regarding short-term risk, HCA is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs PIII Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, PIII has a market cap of 20.2M. Regarding current trading prices, HCA is priced at $380.53, while PIII trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas PIII's P/E ratio is -0.12. In terms of profitability, HCA's ROE is -2.36%, compared to PIII's ROE of -1.29%. Regarding short-term risk, HCA is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs AIH Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, HCA is priced at $380.53, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas AIH's P/E ratio is -2.78. In terms of profitability, HCA's ROE is -2.36%, compared to AIH's ROE of +1.16%. Regarding short-term risk, HCA is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs AMS Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, AMS has a market cap of 15.5M. Regarding current trading prices, HCA is priced at $380.53, while AMS trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas AMS's P/E ratio is 11.42. In terms of profitability, HCA's ROE is -2.36%, compared to AMS's ROE of +0.06%. Regarding short-term risk, HCA is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs CANO Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, HCA is priced at $380.53, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas CANO's P/E ratio is -0.01. In terms of profitability, HCA's ROE is -2.36%, compared to CANO's ROE of -1.49%. Regarding short-term risk, HCA is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs FTRP Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, HCA is priced at $380.53, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas FTRP's P/E ratio is -1.22. In terms of profitability, HCA's ROE is -2.36%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, HCA is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs GBNH Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, HCA is priced at $380.53, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas GBNH's P/E ratio is -0.06. In terms of profitability, HCA's ROE is -2.36%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, HCA is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs RHE Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, HCA is priced at $380.53, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas RHE's P/E ratio is -1.79. In terms of profitability, HCA's ROE is -2.36%, compared to RHE's ROE of +1.52%. Regarding short-term risk, HCA is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs MNDR Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, MNDR has a market cap of 4.9M. Regarding current trading prices, HCA is priced at $380.53, while MNDR trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas MNDR's P/E ratio is -0.16. In terms of profitability, HCA's ROE is -2.36%, compared to MNDR's ROE of -5.70%. Regarding short-term risk, HCA is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs ATIP Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, ATIP has a market cap of 3.8M. Regarding current trading prices, HCA is priced at $380.53, while ATIP trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas ATIP's P/E ratio is -0.04. In terms of profitability, HCA's ROE is -2.36%, compared to ATIP's ROE of +1.77%. Regarding short-term risk, HCA is more volatile compared to ATIP. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs IMACW Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, HCA is priced at $380.53, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas IMACW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -2.36%, compared to IMACW's ROE of +2.46%. Regarding short-term risk, HCA is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs SYRA Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, SYRA has a market cap of 1.2M. Regarding current trading prices, HCA is priced at $380.53, while SYRA trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas SYRA's P/E ratio is -0.31. In terms of profitability, HCA's ROE is -2.36%, compared to SYRA's ROE of -1.04%. Regarding short-term risk, HCA is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs NIVFW Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, NIVFW has a market cap of 1.1M. Regarding current trading prices, HCA is priced at $380.53, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas NIVFW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -2.36%, compared to NIVFW's ROE of -0.39%. Regarding short-term risk, HCA is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs CCM Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, CCM has a market cap of 804.8K. Regarding current trading prices, HCA is priced at $380.53, while CCM trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas CCM's P/E ratio is -0.56. In terms of profitability, HCA's ROE is -2.36%, compared to CCM's ROE of +0.13%. Regarding short-term risk, HCA is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs RHE-PA Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, RHE-PA has a market cap of 674.5K. Regarding current trading prices, HCA is priced at $380.53, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, HCA's ROE is -2.36%, compared to RHE-PA's ROE of +1.52%. Regarding short-term risk, HCA is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs BACK Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, BACK has a market cap of 189.6K. Regarding current trading prices, HCA is priced at $380.53, while BACK trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas BACK's P/E ratio is -0.01. In terms of profitability, HCA's ROE is -2.36%, compared to BACK's ROE of +2.46%. Regarding short-term risk, HCA is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs IONM Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, IONM has a market cap of 149.8K. Regarding current trading prices, HCA is priced at $380.53, while IONM trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas IONM's P/E ratio is N/A. In terms of profitability, HCA's ROE is -2.36%, compared to IONM's ROE of +0.75%. Regarding short-term risk, HCA is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs NVOS Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, NVOS has a market cap of 78.9K. Regarding current trading prices, HCA is priced at $380.53, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas NVOS's P/E ratio is N/A. In terms of profitability, HCA's ROE is -2.36%, compared to NVOS's ROE of -1.20%. Regarding short-term risk, HCA is more volatile compared to NVOS. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs PIIIW Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, PIIIW has a market cap of 33.3K. Regarding current trading prices, HCA is priced at $380.53, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, HCA's ROE is -2.36%, compared to PIIIW's ROE of -1.29%. Regarding short-term risk, HCA is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs NFH Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, NFH has a market cap of 0. Regarding current trading prices, HCA is priced at $380.53, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas NFH's P/E ratio is -19.75. In terms of profitability, HCA's ROE is -2.36%, compared to NFH's ROE of -0.06%. Regarding short-term risk, HCA is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs TLMD Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, HCA is priced at $380.53, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas TLMD's P/E ratio is -1.60. In terms of profitability, HCA's ROE is -2.36%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, HCA is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs TVTY Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, HCA is priced at $380.53, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas TVTY's P/E ratio is 19.06. In terms of profitability, HCA's ROE is -2.36%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, HCA is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs HNGR Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, HCA is priced at $380.53, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas HNGR's P/E ratio is 19.71. In terms of profitability, HCA's ROE is -2.36%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, HCA is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs SLHGP Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, HCA is priced at $380.53, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, HCA's ROE is -2.36%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, HCA is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs SLHG Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, HCA is priced at $380.53, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas SLHG's P/E ratio is -1.48. In terms of profitability, HCA's ROE is -2.36%, compared to SLHG's ROE of N/A. Regarding short-term risk, HCA is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs TLMDW Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, HCA is priced at $380.53, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas TLMDW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -2.36%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, HCA is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.
HCA vs DVCR Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, HCA is priced at $380.53, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas DVCR's P/E ratio is 28.34. In terms of profitability, HCA's ROE is -2.36%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, HCA is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.
HCA vs DCGOW Comparison
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 90.9B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, HCA is priced at $380.53, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 16.57, whereas DCGOW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -2.36%, compared to DCGOW's ROE of -0.00%. Regarding short-term risk, HCA is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.